A breakthrough clinical trial, giving hope to patients with Alzh - ABC6 - Providence, RI and New Bedford, MA News, Weather

A breakthrough clinical trial, giving hope to patients with Alzheimer's

Posted: Updated:

By Ana Bottary

abottary@abc6.com

@anabottary

In His 75 years, Neil Corkery has lived quite a life. A son and a grandson, a 50 year marriage to the love of his life, Maureen. Not to mention a career as a principal and legislator. Although, life took a drastic turn a few years ago when he was diagnosed with Alzheimer's.
 
"It was somewhat negative. I thought, well I started playing music that people might be able to use at my funeral," says Corkery.
 
Corkery says his wife was not ready to give up on him, pushing him to enroll at butler hospital for a double-blind clinical trial. He was 1 of 165 patients receiving either Aducanumab or a placebo.
 
"This tested a new drug which helps lower amyloid plaques and hopefully slow down memory loss in Alzheimer's patients," says Dr. Stephen Salloway, director of Butler Hospital's memory and aging program.
 
Salloway, director of the hospital's memory and aging program was thrilled with the results, the best he's seen in 25 years.

"We had a substantial lowering of plaques in the brain, there seemed to be some slowing in memory loss of those who had removal of plaque," adds Dr. Salloway.

Corkery certainly thinks it worked.

"Believe it or not, I lost weight, I felt better and frankly I think Maureen will attest to this I felt happy," he says.

Dr. Salloway says these results get researchers closer to meeting an ambitious goal of developing a breakthrough treatment by 2025, they're now enrolling for phase 3 recruiting 2,700 people from around the world.
 
"If anybody is looking, don't delay it," says Corkery.

Dr. Salloway says if they can replicate results in phase 3, they can submit them to the FDA for approval.

(c)WLNE-TV 2016

Powered by Frankly

10 Orms Street Providence, R.I. 02904
401-453-8000

All content © Copyright 2000 - 2017 WLNE.
All Rights Reserved.

For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.